Figure 5

In vivo cisplatin resistance model. (A) ES2 cells xenografts were established as described in Methods and mice with control ES2 xenografts or c-MYB transfected ES2 xenografts were challenged with a single dose of 3.0 mg/kg cisplatin. A control group was administered sub-optimum 0.75 mg/kg dose to develop resistance against cisplatin. (B) The c-MYB ES2 xenografts were further compared to c-MYB-anti-miR-21 ES2 xenografts for tumor progression. n = 8 mice per group.